دورية أكاديمية
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
| العنوان: | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. |
|---|---|
| المؤلفون: | Antonia, Scott J, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Yokoi, Takashi, Chiappori, Alberto, Lee, Ki H, de Wit, Maike, Cho, Byoung C, Bourhaba, Maryam, Quantin, Xavier, Tokito, Takaaki, Mekhail, Tarek, Planchard, David, Kim, Young-Chul, Karapetis, Christos S, Hiret, Sandrine, Ostoros, Gyula, Kubota, Kaoru, Gray, Jhanelle E, Paz-Ares, Luis, de Castro Carpeño, Javier, Wadsworth, Catherine, Melillo, Giovanni, Jiang, Haiyi, Huang, Yifan, Dennis, Phillip A, Özgüroğlu, Mustafa, PACIFIC Investigators |
| سنة النشر: | 2017 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | Adult, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Chemoradiotherapy, Disease-Free Survival, Female, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging |
| الوصف: | Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1533-4406 |
| العلاقة: | http://hdl.handle.net/10668/11565Test; https://eprints.qut.edu.au/112192/1/Binder1.pdfTest |
| DOI: | 10.1056/NEJMoa1709937 |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1709937Test http://hdl.handle.net/10668/11565Test https://eprints.qut.edu.au/112192/1/Binder1.pdfTest |
| حقوق: | open access |
| رقم الانضمام: | edsbas.542828B5 |
| قاعدة البيانات: | BASE |
| تدمد: | 15334406 |
|---|---|
| DOI: | 10.1056/NEJMoa1709937 |